These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 37923370)

  • 1. Persistence of SARS-CoV-2 antibodies over 18 months following infection: UK Biobank COVID-19 Serology Study.
    Bešević J; Lacey B; Callen H; Omiyale W; Conroy M; Feng Q; Crook DW; Doherty N; Ebner D; Eyre DW; Fry D; Horn E; Jones EY; Marsden BD; Peto TEA; Starkey F; Stuart D; Welsh S; Wood N; Young A; Young A; Effingham M; Collins R; Holliday J; Allen N
    J Epidemiol Community Health; 2023 Nov; 78(2):105-8. PubMed ID: 37923370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.
    Charlton CL; Nguyen LT; Bailey A; Fenton J; Plitt SS; Marohn C; Lau C; Hinshaw D; Lutsiak C; Simmonds K; Kanji JN; Zelyas N; Lee N; Mengel M; Tipples G
    Microbiol Spectr; 2021 Sep; 9(1):e0029121. PubMed ID: 34406813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Persistence of T-Cell Immunity Responses against SARS-CoV-2 for over 12 Months Post COVID-19 Infection in Unvaccinated Individuals with No Detectable IgG Antibodies.
    Pitiriga VC; Papamentzelopoulou M; Konstantinakou KE; Vasileiou IV; Sakellariou KS; Spyrou NI; Tsakris A
    Vaccines (Basel); 2023 Nov; 11(12):. PubMed ID: 38140169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term Immune Response to SARS-CoV-2 Infection Among Children and Adults After Mild Infection.
    Di Chiara C; Cantarutti A; Costenaro P; Donà D; Bonfante F; Cosma C; Ferrarese M; Cozzani S; Petrara MR; Carmona F; Liberati C; Palma P; Di Salvo G; De Rossi A; Plebani M; Padoan A; Giaquinto C
    JAMA Netw Open; 2022 Jul; 5(7):e2221616. PubMed ID: 35816313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vertical transmission and humoral immune response following maternal infection with SARS-CoV-2: a prospective multicenter cohort study.
    Massalha M; Yefet E; Rozenberg O; Soltsman S; Hasanein J; Smolkin T; Alter A; Perlitz Y; Nachum Z
    Clin Microbiol Infect; 2022 Sep; 28(9):1258-1262. PubMed ID: 35427778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Persistence of IgG COVID-19 antibodies: A longitudinal analysis.
    Carvalho Á; Henriques AR; Queirós P; Rodrigues J; Mendonça N; Rodrigues AM; Canhão H; de Sousa G; Antunes F; Guimarães M
    Front Public Health; 2022; 10():1069898. PubMed ID: 36703818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence and duration of detectable SARS-CoV-2 nucleocapsid antibodies in staff and residents of long-term care facilities over the first year of the pandemic (VIVALDI study): prospective cohort study in England.
    Krutikov M; Palmer T; Tut G; Fuller C; Azmi B; Giddings R; Shrotri M; Kaur N; Sylla P; Lancaster T; Irwin-Singer A; Hayward A; Moss P; Copas A; Shallcross L
    Lancet Healthy Longev; 2022 Jan; 3(1):e13-e21. PubMed ID: 34935001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SARS-CoV-2 Antibody Testing in Health Care Workers: A Comparison of the Clinical Performance of Three Commercially Available Antibody Assays.
    Allen N; Brady M; Carrion Martin AI; Domegan L; Walsh C; Houlihan E; Kerr C; Doherty L; King J; Doheny M; Griffin D; Molloy M; Dunne J; Crowley V; Holmes P; Keogh E; Naughton S; Kelly M; O'Rourke F; Lynagh Y; Crowley B; de Gascun C; Holder P; Bergin C; Fleming C; Ni Riain U; Conlon N;
    Microbiol Spectr; 2021 Oct; 9(2):e0039121. PubMed ID: 34585976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mild SARS-CoV-2 Illness Is Not Associated with Reinfections and Provides Persistent Spike, Nucleocapsid, and Virus-Neutralizing Antibodies.
    Schuler CF; Gherasim C; O'Shea K; Manthei DM; Chen J; Zettel C; Troost JP; Kennedy AA; Tai AW; Giacherio DA; Valdez R; Baldwin JL; Baker JR
    Microbiol Spectr; 2021 Oct; 9(2):e0008721. PubMed ID: 34468184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Seroprevalence, Waning and Correlates of Anti-SARS-CoV-2 IgG Antibodies in Tyrol, Austria: Large-Scale Study of 35,193 Blood Donors Conducted between June 2020 and September 2021.
    Siller A; Seekircher L; Wachter GA; Astl M; Tschiderer L; Pfeifer B; Gaber M; Schennach H; Willeit P
    Viruses; 2022 Mar; 14(3):. PubMed ID: 35336975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Difference in SARS-CoV-2 Antibody Status Between Patients With Cancer and Health Care Workers During the COVID-19 Pandemic in Japan.
    Yazaki S; Yoshida T; Kojima Y; Yagishita S; Nakahama H; Okinaka K; Matsushita H; Shiotsuka M; Kobayashi O; Iwata S; Narita Y; Ohba A; Takahashi M; Iwasa S; Kobayashi K; Ohe Y; Yoshida T; Hamada A; Doi T; Yamamoto N
    JAMA Oncol; 2021 Aug; 7(8):1141-1148. PubMed ID: 34047762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Are SARS-CoV-2 Antibodies Detectable in Human Milk After Vaccination Against COVID-19?
    Scaggs Huang F
    J Pediatric Infect Dis Soc; 2022 Apr; 11(4):126. PubMed ID: 35394545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Persistence of SARS-CoV-2 Antibodies in Vaccinated Health Care Workers Analyzed by Coronavirus Antigen Microarray.
    Hosseinian S; Powers K; Vasudev M; Palma AM; de Assis R; Jain A; Horvath P; Birring PS; Andary R; Au C; Chin B; Khalil G; Ventura J; Luu MK; Figueroa C; Obiero JM; Silzel E; Nakajima R; Gombrich WT; Jasinskas A; Zaldivar F; Schubl S; Felgner PL; Khan S;
    Front Immunol; 2022; 13():817345. PubMed ID: 35493473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating immunity to SARS-CoV-2 in nursing home residents using saliva IgG.
    Katz MJ; Heaney CD; Pisanic N; Smith L; Bigelow BF; Sheikh F; Boudreau A; Kruczynski K; Hsu YJ; Salinas AB; Cosgrove SE; Rock C
    J Am Geriatr Soc; 2022 Mar; 70(3):659-668. PubMed ID: 35038344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trends of humoral immune responses to heterologous antigenic exposure due to vaccination & omicron SARS-CoV-2 infection: Implications for boosting.
    Batra G; Murugesan DR; Raghavan S; Chattopadhyay S; Mehdi F; Ayushi ; Gosain M; Singh S; Das SJ; Deshpande S; Sonar S; Jakhar K; Bhattacharya J; Mani S; Pandey AK; Sankalp ; Goswami S; Das A; Dwivedi T; Sharma N; Kumar S; Sharma P; Kapoor S; Kshetrapa P; Wadhwa N; Thiruvengadam R; Kumar R; Gupta R; Garg PK; Bhatnagar S
    Indian J Med Res; 2023 Jun; 157(6):509-518. PubMed ID: 37322634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kinetics of SARS-CoV-2 Specific and Neutralizing Antibodies over Seven Months after Symptom Onset in COVID-19 Patients.
    Zhu L; Xu X; Zhu B; Guo X; Xu K; Song C; Fu J; Yu H; Kong X; Peng J; Huang H; Zou X; Ding Y; Bao C; Zhu F; Hu Z; Wu M; Shen H
    Microbiol Spectr; 2021 Oct; 9(2):e0059021. PubMed ID: 34550000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection.
    Gallais F; Gantner P; Bruel T; Velay A; Planas D; Wendling MJ; Bayer S; Solis M; Laugel E; Reix N; Schneider A; Glady L; Panaget B; Collongues N; Partisani M; Lessinger JM; Fontanet A; Rey D; Hansmann Y; Kling-Pillitteri L; Schwartz O; De Sèze J; Meyer N; Gonzalez M; Schmidt-Mutter C; Fafi-Kremer S
    EBioMedicine; 2021 Sep; 71():103561. PubMed ID: 34455390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term evolution of humoral immune response after SARS-CoV-2 infection.
    Teyssou E; Zafilaza K; Sayon S; Marot S; Dropy M; Soulie C; Abdi B; Tubach F; Hausfater P; Marcelin AG; Boutolleau D;
    Clin Microbiol Infect; 2022 Jul; 28(7):1027.e1-1027.e4. PubMed ID: 35307573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kinetics of Anti-SARS-CoV-2 IgG Antibodies in Hemodialysis Patients Six Months after Infection.
    Sakhi H; Dahmane D; Attias P; Kofman T; Bouvier M; Lapidus N; Fourati S; El Karoui K;
    J Am Soc Nephrol; 2021 May; 32(5):1033-1036. PubMed ID: 33637518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Healthcare Workers in South Korea Maintain a SARS-CoV-2 Antibody Response Six Months After Receiving a Second Dose of the BNT162b2 mRNA Vaccine.
    Choi JH; Kim YR; Heo ST; Oh H; Kim M; Lee HR; Yoo JR
    Front Immunol; 2022; 13():827306. PubMed ID: 35173736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.